Deborah Telman Biography and Net Worth

Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences

Deborah Telman serves as Executive Vice President of Corporate Affairs and General Counsel, with responsibility for Gilead’s Government Affairs and Policy, Public Affairs, Legal and Compliance functions.

Deb joined Gilead in 2022 and prior to her current role, she served as Executive Vice President, General Counsel and Corporate Secretary at Organon, a women’s healthcare company, building out the Legal, Ethics and Compliance, and Environmental Health and Safety organizations following the company’s separation from Merck. Prior to joining Organon, Deb was the Senior Vice President, General Counsel and Corporate Secretary at Sorrento Therapeutics, a clinical stage biopharmaceutical company.

Over the course of her more than 25-year career, Deb has provided legal counsel both in an in-house capacity and in private practice, including experience in global mergers and acquisitions, governance and litigation. She received her Juris Doctor degree from Boston University School of Law and a bachelor’s degree in mathematics from the University of Pennsylvania.

Deb currently serves on the board of directors of AtriCure Inc., a medical tech company focused on the treatment of atrial fibrillation and related conditions, as well as on the board of directors of Chicago Humanities Festival.

What is Deborah H. Telman's net worth?: The estimated net worth of Deborah H. Telman is at least $5.26 million as of November 12th, 2025. Ms. Telman owns 43,676 shares of Gilead Sciences stock worth more than $5,258,590 as of December 13th. This net worth estimate does not reflect any other assets that Ms. Telman may own. Additionally, Ms. Telman receives an annual salary of $2,560,000.00 as Executive Vice President, Corporate Affairs and General Counsel at Gilead Sciences. Learn More about Deborah H. Telman's net worth.
How old is Deborah H. Telman?: Ms. Telman is currently 59 years old. There are 8 older executives and no younger executives at Gilead Sciences. The oldest executive at Gilead Sciences is Dr. Rudolf Ertl, Senior Vice President of Commercial Operations of Australia, Canada, Europe, who is 78 years old. Learn More on Deborah H. Telman's age.
What is Deborah H. Telman's salary?: As the Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc., Ms. Telman earns $2,560,000.00 per year. There are 4 executives that earn more than Ms. Telman. The highest earning executive at Gilead Sciences is Mr. Daniel P. O'Day, Chairman & CEO, who commands a salary of $6,990,000.00 per year. Learn More on Deborah H. Telman's salary.
How do I contact Deborah H. Telman?: The corporate mailing address for Ms. Telman and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Deborah H. Telman's contact information.
Has Deborah H. Telman been buying or selling shares of Gilead Sciences?: In the last ninety days, Deborah H. Telman has sold $6,590,411.10 of Gilead Sciences stock. Most recently, Deborah H. Telman sold 53,646 shares of the business's stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a transaction totalling $6,590,411.10. Following the completion of the sale, the executive vice president now directly owns 43,676 shares of the company's stock, valued at $5,365,596.60. Learn More on Deborah H. Telman's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Jeffrey Bluestone (Director), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), Kelly Kramer (Director), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Daniel O'Day (Chairman and Chief Executive Officer), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Deborah Telman (Executive Vice President, Corporate Affairs and General Counsel), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 572,042 shares worth more than $61,902,677.51. The most recent insider tranaction occured on November, 28th when Director Kelly A Kramer sold 2,805 shares worth more than $356,515.50. Insiders at Gilead Sciences own 0.3% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 11/28/2025.

Deborah H. Telman Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/12/2025	Sell	53,646	$122.85	$6,590,411.10	43,676

Deborah H. Telman Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $120.40

$119.53

$123.63

50 Day Range

MA: $121.89

$113.58

$128.07

2 Week Range

Now: $120.40

$88.57

$128.70

Volume

6,767,679 shs

Average Volume

6,716,599 shs

Market Capitalization

$149.38 billion

P/E Ratio

18.67

Dividend Yield

2.56%

Beta

0.32

Deborah Telman Biography and Net Worth

What is Deborah H. Telman's net worth?

How old is Deborah H. Telman?

What is Deborah H. Telman's salary?

How do I contact Deborah H. Telman?

Has Deborah H. Telman been buying or selling shares of Gilead Sciences?

Who are Gilead Sciences' active insiders?

Are insiders buying or selling shares of Gilead Sciences?